The hepatitis B virus X protein (HBx) is suggested to regulate transcription by stimulation of intracellular signalling pathways. We have analysed the effects of HBx on activation of the MAP kinase (Erk) and JNK/SAPK signalling pathways and confirm a stimulation of the Erk/MAP kinase in quiescent cells. However, a substantial Erk-independent activation of AP-1, and phosphorylation of c-Jun (serine-63), but not Erk-2, was induced by HBx in dividing, serum-maintained cells. These data suggest that HBx promiscuously activates Erk and JNK responsive pathways and that its overall effect on signalling may be influenced by external mitogenic stimuli.
The hepatitis B virus X protein (HBx) is suggested to regulate transcription by stimulation of intracellular signalling pathways. We have analysed the effects of HBx on activation of the MAP kinase (Erk) and JNK/SAPK signalling pathways and confirm a stimulation of the Erk/MAP kinase in quiescent cells. However, a substantial Erk-independent activation of AP-1, and phosphorylation of c-Jun (serine-63), but not Erk-2, was induced by HBx in dividing, serum-maintained cells. These data suggest that HBx promiscuously activates Erk and JNK responsive pathways and that its overall effect on signalling may be influenced by external mitogenic stimuli.
The hepatitis B virus X protein (HBx) has been classified as a transcriptional activator since it is capable of up-regulating promoters of various cellular and viral genes (Twu et al., 1987 ; Spandau & Lee, 1988 ; Zahm et al., 1988) . HBx is widely regarded as an aetiological factor in hepatitis B virus (HBV)-related carcinogenesis and its putative oncogenic risks are attributed to transcriptional activation of proto-oncogenes (for review see : Rossner, 1992 ; Henkler & Koshy, 1996) and a possible inactivation of the p53 tumour-suppressor protein (Feitelson et al., 1993 ; Wang et al., 1994 ; Truant et al., 1995) . Since the effects of HBx are mediated via a wide range of transcription factor binding sites, promiscuous functional mechanisms have been postulated. Intracellular localization studies demonstrated a predominant cytoplasmic and a relatively minor nuclear population (Doria et al., 1995) . Nuclear HBx is suggested to transactivate via binding to several transcription factors (Maguire et al., 1991 ; Williams & Andrisani, 1995 ; Antunovic et al., 1993 ; Qadri et al., 1995) , whereas the cytoplasmic population was shown to trigger e-mail fhenkle!nimr.mrc.ac.uk intracellular signalling pathways (Benn & Schneider, 1994 ; Doria et al., 1995 ; Kekule! et al., 1992) . The mechanisms of HBx responsive signalling are still not understood. Activation of various components of the Ras\MAP kinase signalling cascade including extracellular regulated kinase 2 (Erk-2) [also called MAP kinase 2] has been reported and is suggested to trigger the induction of AP-1 (Benn & Schneider, 1994 ; Doria et al., 1995) and cell cycle progression (Benn & Schneider, 1995) . A related but distinct signalling pathway is controlled by the Gproteins, Rac, Rho and Ras, which leads to activation of at least two kinases [c-Jun N-terminal kinase (JNKs)] (Derijard et al., 1994 ; Coso et al., 1995 a, b) . These kinases phosphorylate the activating domain of Jun at serine residues 63 and 73, stimulating DNA binding of AP-1 (Whitmarsh & Davis, 1996) . The Erk and the JNK pathway are regulated separately, although cross-talk exists at G-protein and MAP kinase levels (Ramirez et al., 1997 ; Urich et al., 1997 ; Whitmarsh & Davis, 1996) . The JNK pathway [also called SAPK (stress activated protein kinase)] is particularly associated with transduction of stress-related signals Sanchez et al., 1994 ; Whitmarsh & Davis, 1996) , but can also activate Erk in tissue culture. Similarly, the Erk\MAP kinase pathway has been shown to trigger phosphorylation of Jun in some studies (Pulverer et al., 1991) ; however, the N terminus of Jun is not regarded as a substrate of Erk\MAPK in vivo (Whitmarsh & Davis, 1996) . HBx has been recently shown to trigger Nterminal phosphorylation of c-Jun in vitro (Benn et al., 1996) and is suggested to activate the JNK\SAPK pathway. The question arises as to whether induction of both Erk\MAPK and JNK signalling is necessary and required for transcriptional activation of AP-1 binding sites by HBx.
The Ras\Erk kinase signalling pathway utilizes a protein kinase phosphorylation cascade leading to an activation of MAP kinase (Erk-1 and Erk-2) (de Vries-Smits et al., 1992 ; Whitmarsh & Davis, 1996) . Activated Erk-1\2 is phosphorylated and translocated into the nucleus, where it triggers activation of various transcription factors. In our experiments, HBx-induced phosphorylation of Erk-1 was assayed by an adapted Western blot analysis using low bis-acrylamide PAGE to allow efficient separation of phosphorylated and nonphosphorylated endogenous Erk-1 (Fig. 1 A) .
CCL-13 cells (2n5i10') were split into 9 cm dishes containing a 13 mm cover glass to facilitate subsequent immunochemical staining of transfected cells. Cells were grown for 18 h and then transfected by DNA-calcium phosphate coprecipitation with various amounts of the HBx expression vector pCMVX (lanes 4-6). This vector was derived by recloning the hbx gene from pBR-325HBV6 (Valenzuela et al., 1980) into pcDNA3 (Invitrogen). Control cells (lanes 1-3) were transfected with empty pcDNA3 vector. Cells were serum starved for 24 h (lanes 1, 3-6), 18 h post-transfection, and then supplemented with 2n5 % serum for a further 3 h. Positive control cells were treated with 100 ng\ml TPA for 10 min before harvest (lane 3). Untreated CCL-13 cells were continuously maintained in 10 % serum to determine the basal activation of Erk-1 (lane 2). For analysis of Erk-1 phosphorylation, cells were lysed on the plates with pre-heated sample buffer ; the lysates were then sonicated, and 20 µg of total protein separated overnight on a 20 cm polyacrylamide gel. A moderate induction of Erk-1 phosphorylation was observed in HBx-expressing cells, as indicated by the detection of a slower migrating band (lanes 4-6, compare with lane 1). Expression of HBx was confirmed by immunochemical staining, using the anti-HBx directed monoclonal antibody 16F1 (Henkler et al., 1995) . Transfected cells were fixed onto the cover glass with methanol-acetone (1 : 1), and incubated with 16F1 supernatant for 1 h, followed by a 45 min incubation with an HRP-labelled rabbit anti-mouse serum (DAKO). Peroxidase activity of immunocomplexes was visualized by developing the slides in 0n05 % DAB-0n03 % H # O # (Fig. 1 E) . Although HBx was expressed in 40-50 % of cells, the observed effect on Erk-1 phosphorylation may be underestimated, because endogenous Erk-1 from both HBxexpressing and non-expressing cells was detected in this assay. To overcome this limitation, an Erk-2 expression vector containing a cDNA which carries an engineered Myc-epitope (Schaap et al., 1993) was subcloned into the BamHI and EcoRV sites of pcDNA3, thus creating pCMVErk(tag). pCMVErk(tag) and pCMVX were co-transfected into CCL-13 cells, and then serum starvation and induction with 2n5 % serum were carried out as described above (Fig. 1 B) . Phosphorylated and nonphosphorylated Erk-2 were detected with the Myc-epitopespecific antibody 9E10 (Schaap et al., 1993) . A substantial phosphorylation of tagged Erk-2 was observed in HBxexpressing cells under serum starvation (Fig. 1 B, lanes 4-6) .
Comparatively little Erk-2 phosphorylation was induced by HBx artificially targeted into the nucleus using an N-terminal engineered localization signal (Fig. 1 B, lane 3 -compare with lanes 2 and 5). This latter observation was surprising, since HBx trans-activates AP-1 binding sites up to 12-fold using these conditions (unpublished observation). It is notable that Erk-phosphorylation is a transient response to mitogenic signalling, since treatment of serum-starved CCL-13 cells with 10 % serum triggered a rapid and strong phosphorylation of Erk-1 (Fig. 1 D, lane 3) , whereas we typically detect no or very little phosphorylation in serum-maintained cells (lane 4). We conclude that HBx cannot attenuate nor sustain transient effects of serum on Erk-phosphorylation and operates through mechanisms distinct from TPA, as was previously proposed by Murakami et al. (1994) .
A requirement of Erk induction for HBx-mediated transactivation of AP-1 binding sites was analysed in CCL-13 cells, which were treated with PD98059 (New England Biolabs), a selective inhibitor of MEK which specifically inhibits the Erk\MAP kinase signalling pathway (Dudley et al., 1995) . CCL-13 cells were transfected with pCMVErk-2(tag) (Fig. 2 D) and treated with 80 µM PD98059 for 8 h (lane 3) and 1 h (lane 4). Cells were further treated with 50 ng\ml TPA for 5 min (lanes 2-4) prior to harvest, 36 h post-transfection, harvested and phosphorylation of Erk-2 was analysed by mobility shift\Western blot analysis. Treatment with 80 µM PD98059 was sufficient for a complete inhibition of Erk-2 phosphorylation after 1 h (lane 4), and the inhibitor was efficient for at least 8 h (lane 3). Further, CCL-13 cells were transfected with a reporter plasmid containing three AP-1 binding sites (3iAP-1 CAT) (Fig. 2 A, B, lanes 1-5) and co-transfected with pCMVX (lanes 3-5). Positive control cells in lane 2 were transfected with the c-Jun expression vector pRSVjun. The precipitates were removed after 12 h and fresh medium (lanes 1, 2 and 4) or medium containing 100 µM PD98059 (lane 3 and 5) was added to the plates. Control cells (lane 3) were harvested after a further 1 h to determine the basal AP-1 activation, prior to the treatment with MEK inhibitor. Medium containing PD98059 was applied every 8 h to the cells analysed in lane 5. Cells were harvested 36 h post-transfection and activation of AP-1 was determined by CAT assay. The experiment was repeated three times. Inhibition of Erkdependent signalling was controlled in two experiments by treatment of all plates with 50 ng\ml TPA for 5 min, prior to harvest (Fig. 2 C) . Cells were re-suspended in 280 mM Tris pH 7n8 for CAT assay. Thirty µg of total protein was immediately analysed by Western blotting to determine phosphorylation of endogenous Erk-1, confirming that the Erk\MAP kinase pathway was efficiently blocked by PD98059 treatment (lanes 3 and 5) . Inhibition of AP-1 activation by HBx in PD98059-treated cells was substantial (" 50 %) (lane 5) compared with non-treated control cells (lane 4). However, HBx still transactivated AP-1 sites up to 5-fold, indicating that Erk-independent pathways are sufficient for partial transcriptional activation of AP-1 by HBx.
The c-jun proto-oncogene product is a component of the AP-1 transcription factor which consists of either Jun homo-or Jun\Fos heterodimers (Bohman et al., 1987) . Functional activation of Jun, triggered by the JNK signalling pathway, leads to phosphorylation of the N-terminal serine residues 63 and 73 Sanchez et al., 1994 ; Derijard et al., 1994) . The question of whether HBx expression activates The overall expression levels of Jun in samples, described in (A), were analysed by Western blot analysis, using an anti-Jun rabbit polyclonal antiserum (Santa Cruz Biotechnology) and visualized using the ECLdetection system. JNK\SAPK signalling was analysed by Western blotting, using an antibody (New England Biolabs catalogue F916L) which specifically recognizes phosphorylated Jun (serine-63), but not the non-phosphorylated protein (Fig. 3 A) . Since the endogenous levels of Jun were not sufficient to detect any phosphorylation, cells were transfected with pRSVjun (lanes 1-5) and cotransfected with pCMVX(nuc) (lane 3) or pCMVX (lanes 4 and 5), respectively. HBx caused moderate N-terminal phosphorylation of Jun (lane 5), as compared with the combined effect of anisomycin and TPA, used as a positive control (lane 2). Again, only wild-type HBx, but not the nuclear-targeted variant, was capable of inducing phosphorylation of c-Jun (lane 3 -compare with lane 5), showing that activation of JNK responsive signalling is only triggered by the cytoplasmic HBx population. These observations corroborate another recent report suggesting the activation of the JNK kinase pathway by HBx (Benn et al., 1996) . HBxstimulated phosphorylation of Jun was not diminished in cells treated with 80 µM PD98059 (lane 4), which may indicate that its activating effect on JNK signalling is maintained, despite inhibition of the Erk\MAP kinase pathway. Total expression of Jun was analysed by Western blotting, using a rabbit polyclonal antiserum (Santa Cruz Biotechnology) (Fig. 3 B) , and was found to be similar in each analysed sample. Western blot analysis indicated different populations of phosphorylated Jun. A strong band shift was repeatedly found in control cells treated with TPA and anisomycin using both the phospho-63 serine monoclonal antibody and the rabbit polyclonal antiserum (Fig. 3 A, B, lane 2) . Although serine-63 phosphorylated Jun is present in both bands, a more complex phosphorylation pattern was observed, reflecting possible phosphorylation of C-terminal serine residues, or alternatively an additional protein modification of Jun.
The effects of HBx on a variety of signalling pathways such as Erk\MAPK (Benn & Schneider, 1994) , JNK (Benn et al., 1996) and Src-kinases (Klein & Schneider, 1997) have been well-documented. However, the pathological implications of these complex interactions are not understood. The requirement of the classical Erk\MAP kinase pathway for AP-1 activation by HBx was suggested when cotransfection with raf and ras dominant negative mutant recombinant plasmids (Natoli et al., 1994) or prolonged serum depletion (Cross et al., 1993) eradicated the capacity of HBx to stimulate transcription. As Erk\MAPK is essential for c-Fos expression (Gille et al., 1992) , perpetual blockage of Erk\MAPK could lead to depression of AP-1 levels. However, as we demonstrate here, a temporary inhibition of Erk\MAPK does not abolish activation of AP-1. This suggests that HBx can activate AP-1 by alternative mechanisms. By means of in vitro phosphorylation assays, Benn et al. (1996) have previously shown that HBx activates JNK\SAPK. Our results demonstrating the phosphorylation of c-Jun within transfected cells corroborate and substantiate those observations. The data suggest further that the signalling effects of HBx may be modulated by cell cycle or growth control mechanisms, because the capacity of HBx to stimulate Erk\MAP kinase was only observed in quiescent cells (2n5 % serum). In contrast, HBx failed to trigger phosphorylation of Erk-2 in mitotically active cells (10 % serum), but induced serine 63-phosphorylation of c-Jun and Erk-independent activation of AP-1. The JNK\SAPK pathway may constitute the predominant target of HBx, especially in hepatocytes exposed to external mitogenic or inflammatory stimuli, such as in chronic hepatitis B infection. We speculate that this may have physiological significance in the progression of HBV-induced liver disease.
